FV-100

FV-100
Names
	IUPAC name 3-(2-Deoxy-β-D-erythro-pentofuranosyl)-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-2(3H)-one
	Systematic IUPAC name 3-[(2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-2(3H)-one
	Other names Cf1743
Identifiers
CAS Number	956483-02-6 ;
3D model (JSmol)	Interactive image;
PubChem CID	493485;
UNII	0NJ5F6D4U7 ;
CompTox Dashboard (EPA)	DTXSID60185781 ;
	SMILES CCCCCC1=CC=C(C=C1)C2=CC3=CN(C(=O)N=C3O2)[C@H]4C[C@@H]([C@H](O4)CO)O;
Properties
Chemical formula	C22H26N2O5
Molar mass	398.459 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

FV-100, also known as Cf1743, is an orally available nucleoside analogue drug^[1] with antiviral activity.^[2] It may be effective against shingles.^[3]

It was discovered in 1999 in the laboratories of Prof Chris McGuigan, Welsh School of Pharmacy and Prof. Jan Balzarini, Rega Institute, Leuven, Belgium.^[4]

Clinical trials

FV-100 was tested against valaciclovir in a phase II trial in patients with herpes zoster. The trial was sponsored by Bristol-Myers Squibb.^[5] The drug is currently being developed by ContraVir Pharmaceuticals, Inc., Edison, New Jersey.^[6] It has reached Phase III clinical trials.^[7]

References

^ Inhibitex Completes Phase I Clinical Trials For FV-100 And Selects Lead HCV Compounds For Advanced Preclinical Studies, 2009
^ McGuigan, Christopher; Balzarini, Jan (2009). "FV100 as a new approach for the possible treatment of varicella-zoster virus infection". Journal of Antimicrobial Chemotherapy. 64 (4): 671–673. doi:10.1093/jac/dkp294. PMID 19679595.
^ Tyring SK, Lee P, Hill GT Jr, Silverfield JC, Moore AY, Matkovits T, Sullivan-Bolyai J. FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: A randomized-controlled trial. J Med Virol. 2017 Jul;89(7):1255-1264. doi:10.1002/jmv.24750 PMID 27943311
^ Cardiff School of Pharmacy; Pharmaceutical Sciences, Step forward for shingles drug - FV100. Shows structure of FV100.
^ A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster, 23 September 2015
^ ContraVir Pharmaceuticals: FDA Meeting About Antiviral Drug Trial., January 2015
^ De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016 Jul;29(3):695-747. doi:10.1128/CMR.00102-15 PMID 27281742

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

[1] Inhibitex Completes Phase I Clinical Trials For FV-100 And Selects Lead HCV Compounds For Advanced Preclinical Studies, 2009

[2] McGuigan, Christopher; Balzarini, Jan (2009). "FV100 as a new approach for the possible treatment of varicella-zoster virus infection". Journal of Antimicrobial Chemotherapy. 64 (4): 671–673. doi:10.1093/jac/dkp294. PMID 19679595.

[3] Tyring SK, Lee P, Hill GT Jr, Silverfield JC, Moore AY, Matkovits T, Sullivan-Bolyai J. FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: A randomized-controlled trial. J Med Virol. 2017 Jul;89(7):1255-1264. doi:10.1002/jmv.24750 PMID 27943311

[4] Cardiff School of Pharmacy; Pharmaceutical Sciences, Step forward for shingles drug - FV100. Shows structure of FV100.

[5] A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster, 23 September 2015

[6] ContraVir Pharmaceuticals: FDA Meeting About Antiviral Drug Trial., January 2015

[7] De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016 Jul;29(3):695-747. doi:10.1128/CMR.00102-15 PMID 27281742

[1]

[2]

[3]

[4]

[5]

[6]

[7]